ClinicalTrials.gg
Status unknownNCT04132765Updated Nov 27, 2019

Turkish Validation of The Drooling Impact Scale

An observational study in Hypersalivation and Cerebral Palsy, sponsored by Marmara University. Status unknown at 1 site in Turkey. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by Marmara University · Observational

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
4 Years to 16 Years
Sex
All
01

Study summary

The aim of this study is to investigate the reliability and construct validity of the Turkish version of the Drooling Impact Scale in children with cerebral palsy

Read the detailed description

Drooling is common among several neurologic disorders such as cerebral palsy, Parkinson's disease, amyotrophic lateral sclerosis, which are the main diseases that physiatrist are one of the leading physicians involved in whose management 1. Drooling can be seen either as anterior drooling, unintentional leaving of saliva from mouth to outside of the body, or posterior drooling, invisible spill of saliva from mouth through pharyngeal isthmus and then to respiratory or digestive tract, inside the body 2. Anterior drooling causes psycho-social impairment, skin problems, infections, bad odor, dehydration, dentation problems and wet clothes and tools while posterior drooling may result in morbidity by posing a risk for aspiration pneumonia. Despite the frequency and significance of the condition, there is still a paucity of research and inadequate evidence about the various treatments and valid and reliable outcomes available. A major problem for research into interventions to reduce drooling is that there is no valid and reliable measurement tool of saliva control. There is no questionnaire in Turkish to evaluate the effects of drooling as well as drooling interventions.The aim of this study is to investigate the reliability and construct validity of the Turkish version of the Drooling Impact Scale in children with cerebral palsy.

02

Conditions studied

  • Hypersalivation
  • Cerebral Palsy

Keywords

  • cerebral palsy
  • drooling impact scale
  • hypersalivation
  • validity
03

In context

Sialorrhea

60 studies on the registry are indexed under Sialorrhea; 5 are open to participants now.

This study's planned enrollment of 30 is below the median of 90 across 11 observational studies indexed under Sialorrhea.

Browse Sialorrhea studies →

Lead sponsor

Marmara University is the lead sponsor of 599 studies on the registry; 138 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with unilateral or bilateral, spastic, dyskinetic or mixed type cerebral palsy at between the ages of 4-16 and GMFCS level 3,4,5

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unilateral or bilateral cerebral palsy at between the ages of 4-16
  2. Spastic, dyskinetic or mixed type cerebral palsy
  3. GMFCS level 3,4,5
  4. Stable drooling within at least one month

Exclusion criteria

Exclusion Criteria:

  1. Active infection of salivary glands
  2. Upper respiratory tract infection at the time of testing
  3. History of anticholinergic drug intake in the past three weeks
  4. Occurance of any above between test and re-test assessment that may interfere with the results
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with cerebral palsy

    Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5

    Other: Drooling Impact Scale · Other: Drooling Frequency and Severity Scale · Other: The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™) · Other: Drooling Quotient (DQ) · Other: Patient and caregiver visual analog scale (VAS) for drooling · Other: Functional Oral Intake Scale (FOIS) · Other: number of bibs daily used · Other: number of hospital admissions per year related to respiratory infections · Other: Gross Motor Function Classification System (GMFCS) · Other: Manual Ability Classification System (MACS) · Other: Communication Function Classification System (CFCS) · Other: Eating and Drinking Ability Classification System (EDACS)

Interventions

  • OtherDrooling Impact Scale

    A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.

  • OtherDrooling Frequency and Severity Scale

    In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)

  • OtherThe Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)

    A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').

  • OtherDrooling Quotient (DQ)

    DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.

  • OtherPatient and caregiver visual analog scale (VAS) for drooling

    Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)

  • OtherFunctional Oral Intake Scale (FOIS)

    Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.

  • Othernumber of bibs daily used

    Parents will be asked their children's number of bibs daily used.

  • Othernumber of hospital admissions per year related to respiratory infections

    Parents will be asked their children's number of hospital admissions per year related to respiratory infections.

  • OtherGross Motor Function Classification System (GMFCS)

    The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.

  • OtherManual Ability Classification System (MACS)

    The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.

  • OtherCommunication Function Classification System (CFCS)

    The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.

  • OtherEating and Drinking Ability Classification System (EDACS)

    EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.

06

What researchers measure

Primary outcomes

  1. Drooling Impact Scale

    A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.

    Time frame: Day 0

  2. Drooling Impact Scale

    A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.

    Time frame: Day 3

Secondary outcomes

  1. Drooling Frequency and Severity Scale

    n this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)

    Time frame: Day 0

  2. The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)

    A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').

    Time frame: Day 0

  3. Drooling Quotient (DQ)

    DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.

    Time frame: Day 0

  4. Patient and caregiver visual analog scale (VAS) for drooling

    Patients will be asked to score their children's drooling severity on a visual analog scale.

    Time frame: Day 0

  5. Functional Oral Intake Scale (FOIS)

    Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.

    Time frame: Day 0

  6. number of bibs daily used

    Parents will be asked their children's number of bibs daily used.

    Time frame: Day 0

  7. number of hospital admissions per year related to respiratory infections

    Parents will be asked their children's number of hospital admissions per year related to respiratory infections.

    Time frame: Day 0

  8. Gross Motor Function Classification System (GMFCS)

    The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.

    Time frame: Day 0

  9. Manual Ability Classification System (MACS)

    The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.

    Time frame: Day 0

  10. Communication Function Classification System (CFCS)

    The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.

    Time frame: Day 0

  11. Eating and Drinking Ability Classification System (EDACS)

    EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
  • Esra Giray
    Istanbul, 34899, Turkey
    Recruiting
08

References and documents

Publications

  • Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013 May 21;5(5):1010-31. doi: 10.3390/toxins5051010. PubMed 23698357 ↗
  • Erasmus CE, van Hulst K, Rotteveel JJ, Willemsen MA, Jongerius PH. Clinical practice: swallowing problems in cerebral palsy. Eur J Pediatr. 2012 Mar;171(3):409-14. doi: 10.1007/s00431-011-1570-y. Epub 2011 Sep 20. PubMed 21932013 ↗
  • Pesheva P, Kuklinski S, Schmitz B, Probstmeier R. Galectin-3 promotes neural cell adhesion and neurite growth. J Neurosci Res. 1998 Dec 1;54(5):639-54. doi: 10.1002/(SICI)1097-4547(19981201)54:53.0.CO;2-2. PubMed 9843155 ↗

Individual participant data

Plan to share: No — The data that support the findings of this study will be available on request from the corresponding author (EG). The data will not be publicly available due to their containing information that could compromise the privacy of research participants.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2019 (actual). Primary completion is estimated for Aug 2020, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Oct 21, 2019
StartActual
Nov 25, 2019
Primary completionEst.
Aug 30, 2020
CompletionEst.
Aug 30, 2020
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04132765
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Oct 21, 2019
Start date
Nov 25, 2019
Primary completion
Aug 30, 2020 (estimated)
Completion
Aug 30, 2020 (estimated)
Last update
Nov 27, 2019

Study contacts

Esra Giray, MD
Contact
girayesra@hotmail.com
+905558134394
Evrim Karadag-Saygi, Prof
Contact
evrimkaradag4@hotmail.com
+902166570606162
Evrim Karadag Saygi, Prof
study chair · Marmara University
Nida Yektauşakları, PT
principal investigator · Marmara University School of Health Sciences
Fatma Özer, Student
principal investigator · Marmara University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion